Prospective evaluation of liposomal doxorubicin (LD) in patients with metastatic breast cancer previously treated with conventional anthracyclines

12025 Background: The treatment of pts with MBC, who failed previous chemotherapy regimens and whose favourable Performance Status justifies further treatment, represents a significant challenge. In MBC the use of conventional anthracyclines is limited by cumulative cardiac toxicity and myelosuppression, despite long anthracycline-free intervals in many pts. In these cases LD may represent an attractive option. Methods: 15 pts with MBC already treated with different therapeutic strategies and previously exposed to conventional anthracyclines (epirubicin, EPI, in 9 pts and doxorubicin, DOX, in 6 pts), were treated with LD 60 mg/m2 every 3 weeks. Results: Median age was 54 years. Median time from conventional anthracycline exposure was 40 months. Median previous dose of EPI was 440 mg/m2 and of DOX was 240 mg/m2. All pts had a LVEF>50% at baseline. The median number of previous chemotherapy regimens was 4. The median number of cycles of LD administered was 4. G3-G4 hematologic occurred in 6 pts. A delay or ...